To test the mass response outcome of G0/G1 arrest, we exposed the human lung cancer H1666 cell line to 10 uM trametinib, a MEK inhibitor, for 17 h, which arrests most cells in early G1 (Supplementary Fig. 5a)32. This evidence concerns the gene MAP2K7 and lung carcinoma.